[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:large-b-cell-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":162,"states":167},"Large B-cell lymphoma",25,21,[8,16,22,29,35,41,48,54,60,65,71,77,83,89,96,102,108,114,120,126,132,137,144,150,156],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05852717","Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma",[12],"Phase 2","RECRUITING","2026-08-26T02:15:29.632183Z","2026-07-19T19:36:05.120628Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06526793","Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed\u002FRefractory (R\u002FR) B-cell NHL",[12],"2026-08-26T02:15:36.077529Z","2026-07-05T05:32:16.757959Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT07479797","Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy",[26],"Phase 3","2026-08-26T02:15:00.557154Z","2026-05-13T02:55:06.709986Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05464719","A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy",[12],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:28.656811Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06919939","Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed\u002FRefractory Large B-cell Lymphoma",[12],"2026-08-26T02:17:30.961790Z","2026-05-05T02:43:28.640928Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT05794958","Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and\u002For Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel",[45],"Phase 1","2026-08-26T02:19:25.538428Z","2026-05-05T02:43:27.503923Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06610344","BHB & CAR-T for Lymphomas",[],"2026-08-26T02:16:54.044282Z","2026-05-05T02:43:27.447971Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT07052305","NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed\u002FRefractory Large B-cell Lymphoma",[45],"2026-08-26T02:19:08.084946Z","2026-05-05T02:43:27.427697Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":33,"content_modified":64},"NCT06760156","Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym",[12],"2026-05-05T02:43:27.100416Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT06393738","A Study of ARV-393 in Relapsed\u002FRefractory Non-Hodgkin Lymphoma.",[45],"2026-08-26T02:17:36.611194Z","2026-05-05T02:43:29.734935Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":75,"content_modified":76},"NCT06550141","Emapalumab Prevention of CAR-T Cell Associated Toxicities",[12],"2026-08-26T02:19:24.527214Z","2026-05-05T02:43:29.284441Z",{"nct_id":78,"title":79,"phases":80,"status":13,"updated_at":81,"content_modified":82},"NCT06500273","Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL",[12],"2026-08-26T02:17:19.710918Z","2026-05-05T02:43:28.207810Z",{"nct_id":84,"title":85,"phases":86,"status":13,"updated_at":87,"content_modified":88},"NCT05887167","Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed\u002FRefractory Hematological Malignancies",[45],"2026-08-26T02:18:39.640967Z","2026-05-05T02:43:29.648590Z",{"nct_id":90,"title":91,"phases":92,"status":13,"updated_at":94,"content_modified":95},"NCT06564038","A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies",[93],"Phase 1\u002FPhase 2","2026-08-26T02:17:05.997056Z","2026-05-05T02:43:29.532592Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT06542250","A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R\u002FR B-Cell Malignancies.",[93],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:29.470752Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT07098364","ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed\u002FRefractory Large B-Cell Lymphoma",[93],"2026-08-26T02:18:29.369233Z","2026-05-05T02:43:29.072273Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT07188558","A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy",[26],"2026-08-26T02:18:37.277498Z","2026-05-05T02:43:29.052132Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT06191887","B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies",[45],"2026-08-26T02:18:48.678868Z","2026-05-05T02:43:28.173828Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT06340737","AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w\u002FRecurrent\u002FRefractory B Cell Lymphomas",[45],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.925479Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT05643742","A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies",[93],"2026-08-26T02:17:12.307088Z","2026-05-05T02:43:26.685166Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":33,"content_modified":136},"NCT05773040","A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas",[45],"2026-05-05T02:35:31.752653Z",{"nct_id":138,"title":139,"phases":140,"status":141,"updated_at":142,"content_modified":143},"NCT07608731","Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas",[45],"NOT_YET_RECRUITING","2026-08-26T02:19:28.327680Z","2026-05-29T15:36:40.226544Z",{"nct_id":145,"title":146,"phases":147,"status":141,"updated_at":148,"content_modified":149},"NCT07517705","MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma",[12],"2026-08-26T02:15:39.267524Z","2026-06-16T05:54:07.939905Z",{"nct_id":151,"title":152,"phases":153,"status":141,"updated_at":154,"content_modified":155},"NCT07567014","Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS",[12],"2026-08-26T02:18:44.395098Z","2026-05-13T02:55:06.732214Z",{"nct_id":157,"title":158,"phases":159,"status":141,"updated_at":160,"content_modified":161},"NCT07711483","GLORY: Glofit-GemOx With Liso-Cel For Lymphoma",[12],"2026-08-26T02:19:23.493898Z","2026-07-19T19:36:05.096345Z",[163],{"biomarker":164,"count":165,"slug":166},"CD19 Gene",4,"cd19-gene",[168,172,176,180,183,187,190,194,197,200,203,206,209,212,215,218,222,225,228,231,234],{"state":169,"count":170,"slug":171},"Texas",11,"texas",{"state":173,"count":174,"slug":175},"California",8,"california",{"state":177,"count":178,"slug":179},"Florida",7,"florida",{"state":181,"count":178,"slug":182},"New York","new-york",{"state":184,"count":185,"slug":186},"New Jersey",6,"new-jersey",{"state":188,"count":185,"slug":189},"Ohio","ohio",{"state":191,"count":192,"slug":193},"Massachusetts",5,"massachusetts",{"state":195,"count":192,"slug":196},"Missouri","missouri",{"state":198,"count":192,"slug":199},"North Carolina","north-carolina",{"state":201,"count":192,"slug":202},"Pennsylvania","pennsylvania",{"state":204,"count":192,"slug":205},"Tennessee","tennessee",{"state":207,"count":165,"slug":208},"Arizona","arizona",{"state":210,"count":165,"slug":211},"Illinois","illinois",{"state":213,"count":165,"slug":214},"Kansas","kansas",{"state":216,"count":165,"slug":217},"Minnesota","minnesota",{"state":219,"count":220,"slug":221},"Colorado",3,"colorado",{"state":223,"count":220,"slug":224},"Georgia","georgia",{"state":226,"count":220,"slug":227},"Oregon","oregon",{"state":229,"count":220,"slug":230},"Utah","utah",{"state":232,"count":220,"slug":233},"Virginia","virginia",{"state":235,"count":220,"slug":236},"Washington","washington"]